Knuchel J, Zala G, Lammer F, Meyenberger C
Abteilung für Gastroenterologie, Universitätsspital Zürich.
Schweiz Med Wochenschr. 1995 Jun 17;125(24):1206-12.
12 patients with malignant inoperable esophageal obstruction (carcinoma of the esophagus n = 7, carcinoma of the esophagogastric junction n = 3, mediastinal lymph node metastasis n = 2) and high-grade dysphagia were treated with self-expanding metal stents (Ultraflex, Microvasive) made of a nickel titanium alloy (Elastalloy). Other forms of palliation had failed in 9/12 patients. The degree of palliation was expressed as a dysphagia score (0-4) before and after stent insertion. The stents were inserted under endoscopic and fluoroscopic control. They were placed successfully and without complications in all patients. A good functional result was achieved in 11 patients (91.7%). Thus, the dysphagia score decreased significantly from 3.2 +/- 0.4 before to 0.9 +/- 1.0 immediately after stent insertion (p < 0.001). The remarkable relief of dysphagia was sustained during a mean follow up of 101 days (10-278) with a dysphagia score of 1.1 +/- 1.0 at the end of the study (p < 0.001 compared to the score before the procedure). In one patient with mediastinal lymph node metastasis the stent expanded insufficiently. 7 days after insertion it was removed endoscopically and replaced successfully by another stent with a stronger expansive force (Instent). 3 patients experienced recurrent dysphagia (food impaction n = 1 tumor ingrowth through the meshes of the stent n = 2). They were successfully treated by an endoscopical intervention (endoscopical dilatation n = 1, laser therapy n = 1, insertion of a Wallstent n = 1). At the end of the study, 6 patients were alive, 6 patients were dead with a mean survival of 56 days (10-117).
12例无法手术切除的恶性食管梗阻患者(食管癌7例,食管胃交界癌3例,纵隔淋巴结转移2例)且存在严重吞咽困难,接受了由镍钛合金(Elastalloy)制成的自膨式金属支架(Ultraflex,Microvasive公司)治疗。12例患者中有9例此前尝试的其他姑息治疗方法均告失败。以支架置入前后的吞咽困难评分(0 - 4分)来表示姑息治疗的效果。支架在内镜和荧光镜引导下置入。所有患者均成功置入且未出现并发症。11例患者(91.7%)取得了良好的功能效果。吞咽困难评分从置入支架前的3.2±0.4显著降至置入后即刻的0.9±1.0(p < 0.001)。在平均101天(10 - 278天)的随访期内,吞咽困难得到显著缓解,研究结束时吞咽困难评分为1.1±1.0(与手术前评分相比,p < 0.001)。1例纵隔淋巴结转移患者的支架扩张不充分。置入7天后通过内镜将其取出,并成功更换为扩张力更强的另一枚支架(Instent)。3例患者出现吞咽困难复发(食物嵌塞1例,肿瘤通过支架网孔向内生长2例)。通过内镜干预成功治疗(内镜扩张1例,激光治疗1例,置入Wallstent支架1例)。研究结束时,6例患者存活,6例患者死亡,平均生存期为56天(10 - 117天)。